A recent meta-analysis addressed increased risk of death following revascularization with
paclitaxel-coated devices in femopopliteal artery. We evaluated differences in all-cause …

Background Meta-analyses of randomised trials of paclitaxel-coated peripheral devices
found an association with worse long-term survival. Aims We aimed to assess long-term …

Background Clinical benefit of paclitaxel-coated devices for patients with peripheral arterial
disease has been confirmed in randomized controlled trials (RCTs). A meta-analysis …

Background Strategies for the most effective treatment for peripheral arterial disease (PAD)
remain controversial among clinicians. Several trials have shown improved primary patency …

Background A recent meta-analysis reported late excess mortality in patients treated with
paclitaxel-coated devices (PCDs) for symptomatic femoropopliteal disease. However, this …

Background According to a meta-analysis of randomized clinical trials, paclitaxel-coated
devices (PCDs) for lower limb endovascular revascularization may be associated with …

Objective The aim of this study was to determine the survival of patients after use of
paclitaxel coated devices (PCX), as a recent meta-analysis of randomised trials reported …

The role of paclitaxel in the treatment of femoropopliteal peripheral arterial disease is
currently ambiguous. A summary-level meta-analysis of randomised trials published in 2018 …

Objective The treatment of femoropopliteal peripheral artery disease (PAD) using paclitaxel-
coated devices (PCDs) has been shown to improve patency in several randomized trials …

Purpose To investigate the real-world safety of paclitaxel (PTX)-coated devices for treating
lower extremity peripheral artery disease using a commercial claims database. Materials …